<DOC>
	<DOCNO>NCT02467842</DOCNO>
	<brief_summary>All participant receive single dose assigned vaccine Day 0 . They follow immunogenicity safety Day 21 post-vaccination . The serious adverse event collect 6 month post-vaccination .</brief_summary>
	<brief_title>Immunogenicity Safety Quadrivalent Influenza Vaccine ( NBP607 ) Adults Elderly Subjects</brief_title>
	<detailed_description>In randomize controlled phase III trial undertake 10 university hospital South Korea , adult elderly subject randomly assign 2:1:1 ratio NBP607-QIV versus cell culture-based trivalent inactivate influenza vaccine , NBP607-Y NBP607-V. Immunogenicity assess 3 week vaccination hemagglutination inhibition ( HI ) assay . Safety assess 6 month post-vaccination : solicited adverse event 7 day , unsolicited AEs 21 day SAE 6 month .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Adults age 19 year old Those able comply requirement study If woman , negative pregnancy test willingness use birth control measure entire study duration Disorders immune function Any malignancy lymphoproliferative disorder History GuillainBarré syndrome Individuals know bleeding diathesis , condition may associate prolonged bleeding time Experience fever ( &gt; 38.0 ℃ ) within 24 hour follow vaccination Body temperature &gt; 38.0 ℃ vaccination day Concomitant medications/therapy immunosuppressant immune modify drug , systemic corticosteroid , immunoglobulin , blood blood derive product within 3 month Influenza vaccination within 6 month Subjects participate interventional study within 4 week Any vaccination within 1 month Those plan receive vaccine within 1 month study vaccine Individuals serious chronic progressive disease Pregnant breastfeed woman Any reason opinion investigator might interfere study</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Influenza vaccine</keyword>
	<keyword>Quadrivalent</keyword>
	<keyword>Inactivated cell culture-derived</keyword>
</DOC>